Published: 06/23/2026 | Author: Quentin Blount

Despite some early breakthroughs to treat methamphetamine addiction, clinicians still have no specific designated medication for this disorder, a gap that has frustrated health providers and victims for decades. But now, new laboratory research suggests an unexpected place to look for one: a link between brain inflammation and the immune system.

A Long Search for a Meth Medication

Unlike alcohol and opioid use disorders, which have several approved medications, methamphetamine addiction has none. For opioids, clinicians can prescribe buprenorphine or methadone. For alcohol, naltrexone or acamprosate. 

People in treatment for meth currently rely on behavioral approaches such as counseling and contingency management, which rewards continued abstinence. A new study, however, points toward a possible biological target.

The Study’s Findings

Methamphetamine is a powerful stimulant that floods the brain’s reward system with dopamine and, with repeated use, drives inflammation throughout the body. Stimulant use disorder can affect anyone, and early abstinence often brings fatigue, low mood and a loss of pleasure that reflect a reward system in recovery.

Here’s where the researchers step in. A team led by Habibeh Khoshbouei at the University of Florida College of Medicine studied the ventral tegmental area, a cluster of dopamine neurons at the base of the brain’s reward system. Using electrical recordings from mouse brain slices, they watched methamphetamine speed up those neurons and change the shape of their electrical activity.

The researchers then applied TNF-alpha, an inflammatory molecule, with no drug present. The dopamine neurons reacted almost exactly as they had to meth. A compound called UCB-9260 blocks TNF-alpha signaling, which dulled meth’s effect on the cells and blocked the dopamine transporter that meth hijacked. 

By using a sensor that detects dopamine release, the team confirmed that blocking TNF-alpha reduced the dopamine surge meth produced. Khoshbouei described the two systems as engaged in bidirectional crosstalk.

An Existing Drug Class Matters

The finding stands out because TNF-alpha blockers already exist. Medications such as etanercept and adalimumab have been prescribed for years for rheumatoid arthritis and Crohn’s disease, so health providers already understand their safety profiles. Now, TNF-alpha blockers have a new role in reducing the impact of stimulants on the brain.

As for the next steps, Khoshbouei’s team plans to seek NIH funding to test whether these existing drugs can reduce meth’s rewarding pull and lower relapse rates. Repurposing an approved medication is generally faster than developing a new one.

Indeed, it helps to keep Khoshbouei’s work in perspective. This early, preclinical work involved mouse tissue and cell cultures, not people. The researchers caution that no one should take an arthritis drug to manage cravings because blocking TNF-alpha also affects the body’s defenses against infection.

Treatment for Methamphetamine Addiction

For now, the most effective help for methamphetamine addiction combines behavioral therapy, contingency management and peer support. 

Narcotics Anonymous, a 12-step program open to people recovering from any drug, can be part of that support. For those not sure about meeting peers in their neighborhood, consider that NA meetings are free, widely available and welcome people who use stimulants as well as opioids.

NA: The First Step

If you or someone you love has a methamphetamine addiction, seek help today. Find NA meetings in your area, explore stimulant treatment programs, and ask providers about contingency management. Call 800-934-1582(Sponsored) to speak with an expert or feel free to browse our directory for NA chapters across the nation.